Buyback yield (TTM)
1.23%
Shareholder yield (TTM)
1.84%
5Y share count change
1.3%
Buyback spend (TTM)
$100.08M
Cumulative buybacks
$1.01B
Key takeaways
- Bio-Techne (TECH) repurchased about $100.08M of stock over the trailing twelve months.
- Diluted share count is up 1.3% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 2.46× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +40.6% per year over the latest 5-year window.
- TTM repurchases used about 46% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Bio-Techne (TECH)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Bio-Techne (TECH)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Bio-Techne (TECH)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Bio-Techne (TECH)
Latest: $275.73M
Overview
Bio-Techne (TECH) most recent annual buyback spend stands at $275.73M (2025) – surged 244.5% year-over-year.
Over 2020–2025 (5 years), Bio-Techne buyback spend expanded at a +40.6% compound annual rate, sustaining 2 straight years of year-over-year growth.
$275.73M stands as the all-time-high annual buyback spend, posted in 2025, against a low of $0.00 during 1991.
Bio-Techne Buyback Spend 2025: $275.73M
In 2025, Bio-Techne reported buyback spend of $275.73M, surged 244.5% from 2024. This figure represents the highest annual value in the available history.
Bio-Techne Buyback Spend 2024: $80.04M
Bio-Techne buyback spend in 2024 was $80.04M, surged 309.2% from 2023.
Bio-Techne Buyback Spend 2023: $19.56M
2023's buyback spend for Bio-Techne came in at $19.56M, plunged 87.8% below 2022.
Bio-Techne Buyback Spend 2022: $160.95M
Bio-Techne posted buyback spend of $160.95M in 2022, surged 272.8% from 2021.
Bio-Techne Buyback Spend 2021: $43.18M
Bio-Techne buyback spend in 2021 was $43.18M.
See more financial history for Bio-Techne (TECH).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $275.73M | $40.83M | $234.90M | 3.46% | 0.16B | -0.7% | |
| 2024 | $80.04M | $38.04M | $42.00M | 0.71% | 0.16B | -0.7% | |
| 2023 | $19.56M | $39.23M | −$19.67M | 0.15% | 0.16B | -1.4% | |
| 2022 | $160.95M | $42.18M | $118.77M | 1.18% | 0.16B | +1.3% | |
| 2021 | $43.18M | $48.98M | −$5.80M | 0.25% | 0.16B | +2.7% | |
| 2020 | $50.11M | $32.37M | $17.75M | 0.50% | 0.16B | +1.3% | |
| 2019 | $15.40M | $32.28M | −$16.88M | 0.19% | 0.16B | +2.2% | |
| 2018 | $0.00 | $28.24M | −$28.24M | — | 0.15B | +1.5% | |
| 2017 | $0.00 | $14.63M | −$14.63M | — | 0.15B | +0.5% | |
| 2016 | $0.00 | $9.43M | −$9.43M | — | 0.15B | +0.3% | |
| 2015 | $0.00 | $5.96M | −$5.96M | — | 0.15B | +0.6% | |
| 2014 | $0.00 | $3.52M | −$3.52M | — | 0.15B | +0.3% | |
| 2013 | $2.39M | $1.86M | $530.00K | 0.09% | 0.15B | -0.3% | |
| 2012 | $24.50M | $1.64M | $22.86M | 0.90% | 0.15B | -0.4% | |
| 2011 | $2.23M | $1.14M | $1.10M | 0.07% | 0.15B | -0.5% | |
| 2010 | $15.58M | $1.14M | $14.45M | 0.73% | 0.15B | -1.5% | |
| 2009 | $92.31M | $1.48M | $90.83M | 3.88% | 0.15B | -3.4% | |
| 2008 | $60.19M | $0.00 | $60.19M | 2.01% | 0.16B | -0.7% | |
| 2007 | $1.22M | $0.00 | $1.22M | 0.05% | 0.16B | -0.2% | |
| 2006 | $27.27M | $0.00 | $27.27M | 1.36% | 0.16B | -3.2% | |
| 2005 | $103.93M | $0.00 | $103.93M | 5.84% | 0.16B | -1.9% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 0.17B | -0.8% | |
| 2003 | $23.66M | $0.00 | $23.66M | 1.90% | 0.17B | -1.2% | |
| 2002 | $745.62K | $0.00 | $745.62K | 0.06% | 0.17B | -0.3% | |
| 2001 | $1.16M | $0.00 | $1.16M | 0.09% | 0.17B | +1.1% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 0.17B | +2.0% | |
| 1999 | $3.90M | $0.00 | $3.90M | — | 0.17B | +5.5% | |
| 1998 | $300.00K | $0.00 | $300.00K | — | 0.16B | +0.7% | |
| 1997 | $3.20M | $0.00 | $3.20M | — | 0.16B | +0.1% | |
| 1996 | $700.00K | $0.00 | $700.00K | — | 0.16B | — | |
| 1995 | $600.00K | $0.00 | $600.00K | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $200.00K | $0.00 | $200.00K | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $200.00K | $0.00 | $200.00K | — | — | — |
- 2025$275.73M
- 2024$80.04M
- 2023$19.56M
- 2022$160.95M
- 2021$43.18M
- 2020$50.11M
- 2019$15.40M
- 2018$0.00
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$0.00
- 2013$2.39M
- 2012$24.50M
- 2011$2.23M
- 2010$15.58M
- 2009$92.31M
- 2008$60.19M
- 2007$1.22M
- 2006$27.27M
- 2005$103.93M
- 2004$0.00
- 2003$23.66M
- 2002$745.62K
- 2001$1.16M
- 2000$0.00
- 1999$3.90M
- 1998$300.00K
- 1997$3.20M
- 1996$700.00K
- 1995$600.00K
- 1994$0.00
- 1993$0.00
- 1992$200.00K
- 1991$0.00
- 1990$200.00K
Buybacks vs stock-based compensation for Bio-Techne (TECH)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 2.46×.
Buybacks vs dividends (share of cash returned) for Bio-Techne (TECH)
How Bio-Techne splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Bio-Techne, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $219.78M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation